Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YNT-185 is a nonpeptide, selective agonist of the orexin type-2 receptor (OX2R), demonstrating EC50 values of 0.028 μM and 2.75 μM for OX2R and OX1R, respectively. Furthermore, YNT-185 effectively alleviates symptoms of narcolepsy-cataplexy in mouse models.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 60.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 239.00 | |
25 mg | In stock | $ 478.00 | |
50 mg | In stock | $ 772.00 | |
100 mg | In stock | $ 1,050.00 |
Description | YNT-185 is a nonpeptide, selective agonist of the orexin type-2 receptor (OX2R), demonstrating EC50 values of 0.028 μM and 2.75 μM for OX2R and OX1R, respectively. Furthermore, YNT-185 effectively alleviates symptoms of narcolepsy-cataplexy in mouse models. |
Targets&IC50 | OX2R:0.028(EC50), OX1R:2.75 μM(EC50) |
In vivo |
YNT-185 (20-40 mg/kg; i.p.) enhances alertness in mice.[1]. In a dose-dependent manner, YNT-185 (300 nmol; i.c.v.) significantly extends wakefulness for a period of 3 hours, accompanied by a reduction in non-rapid eye movement (NREM) sleep duration, in wild-type mice but not in OXRDKO mice.[1] |
Molecular Weight | 615.74 |
Formula | C33H37N5O5S |
CAS No. | 1804978-81-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.0 mg/mL (90.0 mM)
H2O: Insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YNT-185 1804978-81-1 GPCR/G Protein Neuroscience OX Receptor YNT 185 YNT185 inhibitor inhibit